

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A pharmaceutical composition for treating chronic hepatitis C, comprising at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators and lectin-binding substances.
2. (Original) The pharmaceutical composition according to Claim 1, comprising IL-15.
3. (Original) The pharmaceutical composition according to Claim 2 for use together with IFN- α in treatment of chronic hepatitis C, comprising IL-15.
4. (Original) The pharmaceutical composition according to Claim 1, comprising a myeloid dendritic cell maturation stimulator.
5. (Original) The pharmaceutical composition according to Claim 4 for use together with IFN- α in treatment of chronic hepatitis C, comprising a myeloid dendritic cell maturation stimulator.
6. (Currently Amended) The pharmaceutical composition according to Claim 4 or 5, wherein the myeloid dendritic cell maturation stimulator is selected from the group consisting of CpG oligo deoxynucleotide, GM-CSF, IL-4, LPS, CD40L, polyI:C, TNF- α and IFN- γ .
7. (Original) The pharmaceutical composition according to Claim 1, comprising a lectin-binding substance.

8. (Original) The pharmaceutical composition according to Claim 7 for use together with IFN- α in treatment of chronic hepatitis C, comprising a lectin-binding substance.

9. (Currently Amended) The pharmaceutical composition according to Claim 7 ~~or~~ 8, wherein the lectin-binding substance is selected from the group consisting of mannose carbohydrates, fucose carbohydrates and anti-lectin antibodies.

10. (Original) A pharmaceutical composition for preventing hepatic cirrhosis or hepatic cell carcinoma, comprising at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators and lectin-binding substances.

11. (Original) A method of treating chronic hepatitis C, comprising administration to a patient of an effective amount of at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators and lectin-binding substances.

12. (Original) Use of IL-15, myeloid dendritic cell maturation stimulator and/or lectin-binding substance in manufacture of a medicine for treatment of chronic hepatitis C.